Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
7 papers
Recent·Most cited
B. Wu, S. Tapadar, Z. Ruan, C. Sun, R. Arnold, A. Johnston, J. Olugbami, U. Arunsi, D. Gaul, J. Petros, T. Kobayashi, D. G. Duda, A. K. Oyelere
This paper identifies a novel HDAC inhibitor, STR-V-53, that effectively targets HCC and enhances immunotherapy responses in mouse models.
bioRxiv · Mar 27, 2024Cancer Biology
S. Morita, T. Ando, H. Kikuchi, A. Morita, T. Kobayashi, G. Birch, R. Tanaka, A. Matsui, Z. Ruan, P. Huang, Y. Cho, A. Hernandez, J. W. Lee, E. M. Coyne, S. M. Shin, , D. G. Duda
Liver fibrosis limits the survival benefit of multikinase inhibitor immunotherapy in hepatocellular carcinoma by promoting innate immune-mediated hepatotoxicity despite preserved tumor control.
bioRxiv · Oct 20, 2023 · PreprintCancer Biology
B. M. Nagalo, Y. Zhou, E. L. Loeuillard, C. Dumbauld, O. Barro, N. Elliott, A. T. Baker, M. Arora, J. M. Bogenberger, N. Meurice, J. Petit, P. L. S. Uson Junior, F. Aslam, J. C. Chamcheu, C. C. Simoes, , M. Borad
This study characterizes Morreton virus (MORV) as a safe and effective oncolytic virotherapy for liver cancers, showing tumor regression in animal models with lower doses than VSV.
Hepatology · Jun 1, 2023Peer-reviewedImmunology
J. Chen, Z. Amoozgar, X. LIU, S. Aoki, Z. Liu, S. Shin, A. Matsui, Z. Pu, P.-J. Lei, M. Datta, L. Zhu, Z. Ruan, L. Shi, D. Staiculescu, K. Inoue, , D. G. Duda
This paper shows that combining chemotherapy with CTLA-4 blockade reprograms the immune microenvironment of intrahepatic cholangiocarcinoma, enhancing the effectiveness of anti-PD1 therapy.
bioRxiv · Jan 26, 2023Cancer Biology
S. Sivanand, Y. Gultekin, P. Winter, S. Y. Vermeulen, K. Tchourine, K. L. Abbott, L. V. Danai, F. Gourgue, B. T. Do, K. Crowder, T. Kunchok, A. N. Lau, A. M. Darnell, A. Jefferson, S. Morita, , M. G. Vander Heiden
This study shows that cancer tissue-of-origin influences the metabolism and growth preferences of both primary and metastatic tumors.
bioRxiv · Aug 17, 2022Cancer Biology
D. G. Duda, K. Inoue, D. H. Schanne, A. Matsui, P. Lei, S. Klein, S. Aoki, H. Taniguchi, H. Kikuchi, J. Chen, Z. Liu, S. Q. Tsai, T. C. Schmidt, M. Iwasaki, G. Geidel, , N. Bardeesy
The paper shows that the IFNA pathway promotes aggressive KRASG12D-mutant pancreatic ductal adenocarcinomas through IFNAR1/STAT3 activation and identifies IFNAR1 inhibition as a potential therapeutic strategy.
bioRxiv · Jun 29, 2022 · PreprintCancer Biology
Z. Pu, Z. Liu, J. Chen, K. Inoue, Z. Ruan, L. Zhu, H. Kikuchi, A. Matsui, P. Huang, D. G. Duda
This study tests an NLRP3 agonist added to PD-1/VEGFR inhibitors in murine HCC models with liver damage, finding it feasible but ineffective in improving tumor outcomes.
bioRxiv · Jun 23, 2022 · PreprintImmunology